Target ALS Longitudinal Biomarkers

Target ALS Biomarker Study: Longitudinal Biofluids, Clinical Measures, and At-Home Measures

The purpose of this study is to generate a biorepository of longitudinal blood (plasma and serum), cerebral spinal fluid (CSF), and urine linked to genetics and clinical information, and at-home functional measures that are then made available to the ALS research community. Both ALS participants and healthy control participants will be enrolled over a 5-year period.

ALS participants will complete a total of 5 clinic visits across a 16-month period. Healthy control participants will complete a total of 2 clinic visits across a 12-month period. At-home speech assessments will be collected bi-weekly for both groups. And, for a subset of participants, at-home vital capacity assessments will also be collected on a biweekly weekly basis for both groups. These samples and clinical information will be de-identified and made available for investigators to use in future research studies.

Principal Investigator:
Robert Bowser, PhD

Site Principal Investigator:
Shafeeq Ladha, MD

Enrollment Contact:
Whitney Dailey
(602) 406-7804
Fulton.Research@CommonSpirit.org